RDGL — VIVOS INC

OTC · Health Care · Health Care Equipment & Supplies · CIK 1449349 ·
Last close
$0.05
Market Cap
$25.95M
52W High
$0.12
52W Low
$0.05
ADV30
1,264,064
Next earnings
Vivos Inc., a radiation oncology medical device company, engages in the development of yttrium-90-based precision radionuclide therapy devices for the treatment of non-resectable tumors in the United States. The company develops RadioGel, which is an injectable particle-gel for Precision Radionuclide Therapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. It is also developing PLGA-g-PEG polymers; PrecisionGel, a hydrogel polymer platform for delivering active pharmaceutical ingredients and therapeutic agents; Duncan Chiller, a general laboratory equipment for non-water localized chilling; and other products under the Alpha-Gel, Beta-Gel, Gamma-Gel, and Peltier Chiller brands. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Kennewick, Washington.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 36,068 -8,018 -545,492 -1,184,845 2,950,505 2,525,782 253,195
Dec 2025 24,752 -3,105 -1,095,719 -1,078,514 1,867,583 1,558,525 206,743
Sep 2025 1,879 -12,815 -531,023 -507,294 2,295,185 2,202,109 112,693
Jun 2025 15,000 -34,753 -674,772 -645,513 2,775,556 2,660,590 96,458

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-2,032,406
Investing CF
$-151,205
Financing CF
$1,547,478
CapEx
$-151,205
Dividends Paid
Buybacks
EPS Diluted TTM
$0.00
As of
2026-08-16

Balance + Analyst (yfinance extras)

Retained Earnings
$-89,612,091
Inventory
$56,863
Receivables
$7,668
ST Investments
EBIT TTM
$-2,847,006
Pretax Income TTM
$-3,416,166
Interest Exp TTM
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$99,099
EBITDA
Free Cash Flow
$-1,544,673
Enterprise Value
$33,359,872
Total Cash
$2,336,022
Total Debt
$103,153
Shares Out
494,214,360
Trailing EPS
$-0.01
Book Value
$-0.01
ROE
-132.5%
ROA
-62.5%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 68,379 -3,165,047 -3,066,017 1,867,583 206,743 -2,057,743
Dec 2024 27,995 -2,604,384 -2,910,448 2,233,456 86,209 -1,684,039
Dec 2023 19,500 -2,793,146 -2,894,753 1,610,124 245,004 -1,293,023
Dec 2022 36,499 -2,517,749 -2,470,161 1,742,736 81,692 -1,120,058

Peers — same industry

TickerNameMarket CapLastDaily %
PSTV CERENOME, INC. $26.42M $3.84
PETV PetVivo Holdings, Inc. $26.47M $0.70
HRGN Harvard Apparatus Regenerative Technology, Inc. $26.71M $1.52
FEMY FEMASYS INC $24.96M $2.98
GTHP GUIDED THERAPEUTICS INC $24.13M $0.25

News headlines (Yahoo Finance, 1h cache)

Vivos Begins IsoPet Shipments and Secures India Manufacturing Authorization
2026-08-18 14:47 · Yahoo
Vivos Inc. Achieves Two Major Operational Milestones: First IsoPet® Shipments from New U.S. Production Facility and Authorization from India’s Nuclear Regulatory Authority for International Manufactur
2026-08-18 12:30 · Yahoo
Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call
2026-08-14 12:45 · Yahoo
Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update - Correction
2026-07-27 14:49 · Yahoo
Vivos Reports FDA IDE Approval and Expands Precision Radionuclide Therapy Programs
2026-07-27 14:44 · Yahoo
Vivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel® Precision Radionuclide Therapy™
2026-07-06 12:30 · Yahoo
Vivos Receives Washington Radioactive Materials License for IsoPet Manufacturing, Enabling Domestic Production Expansion (RDGL)
2026-06-11 14:51 · Yahoo
Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel® Precision Radionuclide Therapy™
2026-06-05 12:30 · Yahoo
Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity
2026-06-22 12:30 · Yahoo
Vivos Therapeutics Secures New U.S. Patent Expanding Protection for Vivos CARE Technology
2026-08-05 14:48 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.